BFLY — Butterfly Network, Inc.

Is BFLY overbought or oversold? Here is the current MarketMoodz read.

Healthcare · Medical Devices

Neutral As of August 19, 2026

Butterfly Network, Inc. (BFLY) currently reads Neutral on the MarketMoodz overbought/oversold meter, as of August 19, 2026. The Healthcare name (Medical Devices) last closed at $9.17. The rating moved from Oversold to Neutral on August 18, 2026.

AI analysis

Butterfly Network occupies a differentiated niche in portable, AI-enabled ultrasound with clear long-term addressable market in point-of-care imaging and procedure guidance. Revenue upside hinges on scaling device placements and converting to recurring software/subscription streams; sector themes for diagnostics and AI-enabled imaging provide constructive demand context. Near-term performance will be driven by execution on commercial rollouts, cash management, and how quickly recurring revenue can offset device-selling cyclicality. Competitive pressure, reimbursement dynamics, and regulatory or privacy headwinds are the main constraints that could slow adoption or require additional capital.

Key factors

  • Unique portable ultrasound hardware (single silicon-based probe) that has driven differentiated product adoption in point-of-care imaging
  • Recurring software and subscription revenue potential (AI-enabled imaging, cloud analytics) that can expand margins over time
  • Sector tailwinds: increased diagnostic & image-guided procedure demand and adoption of AI-enabled navigation/diagnostics
  • Partnership and distribution opportunities with hospitals, outpatient centers, and telehealth providers to scale device placements
  • Product-led growth potential from improved algorithms and additional cleared clinical indications (procedural guidance, screening)
  • Relatively low public-company valuation compared with potential upside if recurring revenue scale is achieved

Risks

  • Uncertain near-term financial health and cash runway risk; need for capital raises could dilute shareholders
  • Intense competition from incumbent imaging vendors (GE, Philips, Siemens) and new low-cost portable competitors
  • Reimbursement limitations and slow adoption by conservative hospital procurement processes
  • Regulatory and clearance risk for new clinical features and AI tools; potential delays slow commercialization
  • Macro weakness or reduced capital spending at hospitals could depress device sales
  • Data privacy and FTC-style enforcement risks affecting digital-health integrations and partner relationships
  • Execution risk around scaling service revenue, maintaining device margins, and converting pilots into large deployments

Latest MarketMoodz coverage

See today's live rating, score and targets

Members see the live hourly rating for BFLY — the numeric AI score plus targets and entry zones — while this public page updates nightly.

Start the 14-day trial

This page is for informational purposes only and is not investment, financial, tax, or legal advice. Ratings and research outputs can be wrong, incomplete, or stale. Past performance does not guarantee future results. Always do your own research and consider consulting a qualified professional.